OraSure Technologies (Nasdaq: OSUR ) is expected to report Q1 earnings on May 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict OraSure Technologies's revenues will contract -0.6% and EPS will remain in the red.
The average estimate for revenue is $20.8 million. On the bottom line, the average EPS estimate is -$0.18.
Last quarter, OraSure Technologies booked revenue of $22.1 million. GAAP reported sales were 6.5% lower than the prior-year quarter's $23.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.11. GAAP EPS were -$0.11 for Q4 versus $0.00 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 59.9%, 210 basis points worse than the prior-year quarter. Operating margin was -27.7%, much worse than the prior-year quarter. Net margin was -26.5%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $95.4 million. The average EPS estimate is -$0.50.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 199 members out of 220 rating the stock outperform, and 21 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give OraSure Technologies a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on OraSure Technologies is outperform, with an average price target of $11.93.
Is OraSure Technologies the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add OraSure Technologies to My Watchlist.